Clinical course and outcomes of COVID-19 in hematopoietic cell transplant patients, a regional report from the Middle East.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
03
03
2021
accepted:
12
04
2021
revised:
23
03
2021
pubmed:
29
4
2021
medline:
7
9
2021
entrez:
28
4
2021
Statut:
ppublish
Résumé
The coronavirus disease-2019 (COVID-19) caused by SARS Coronavirus 2 (SARS-CoV-2) is a potentially lethal infection. Cancer patients, and specifically hematopoietic cell transplant (HCT) recipients are severely immunocompromised and may be at a higher risk of a complicated course with this infection. We aimed to study the COVID-19 outcomes and severity in post HCT patients. We retrospectively reviewed post-HCT patients diagnosed with COVID-19 between March 15, 2020, and December 1, 2020 at 10 transplant centers across the Middle East. We identified 91 patients with confirmed SARS-CoV-2 infection across 10 transplant centers. The median age upon presentation with COVID-19 was 35. Fifty two patients were post allo-HCT while the remaining 39 patients were post auto-HCT. The median time from transplant was 14.9 months. Mortality rate was 4.4%. Hospital admission rate was 53%. ICU admission rate was 14%. Mechanical ventilation rate was 10%. Oxygen supplementation rate was 18%. Time from HCT to COVID-19 >6 months was associated with lower admission rates and lower rates of the "severity" composite endpoint. Antibody responses was seen 67% of evaluable patients. In this series of HCT recipients, we report overall favorable clinical outcomes for patients with COVID-19 and provide preliminary insights into the clinical course of this disease in this specific population.
Identifiants
pubmed: 33907304
doi: 10.1038/s41409-021-01312-y
pii: 10.1038/s41409-021-01312-y
pmc: PMC8078827
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2144-2151Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Lu H, Stratton CW, Tang Y-W. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol. 2020;92:401–2.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13.
doi: 10.1016/S0140-6736(20)30211-7
World Health Organization. Coronavirus disease 2019 (COVID-19): situation report, 82. 2020.
Ortiz-Prado E, Simbana-Rivera K, Gomez-Barreno L, Rubio-Neira M, Guaman LP, Kyriakidis NC, et al. Clinical, molecular and epidemiological characterization of the SARS-CoV2 virus and the Coronavirus disease 2019 (COVID-19), a comprehensive literature review. Diagnostic Microbiol Infect Dis. 2020;98:115094.
doi: 10.1016/j.diagmicrobio.2020.115094
World Health Organization. Informal consultation on prioritization of candidate therapeutic agents for use in novel coronavirus 2019 infection. 2020. In, 2020.
Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. N Engl J Med. 2020;382:1969–73.
doi: 10.1056/NEJMp2005630
Bhatti JS, Bhatti GK, Khullar N, Reddy AP, Reddy PH. Therapeutic strategies in the development of anti-viral drugs and vaccines against SARS-CoV-2 infection. Mol Neurobiol. 2020;57:1–22. https://doi.org/10.1007/s12035-020-02074-2.
doi: 10.1007/s12035-020-02074-2.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15.
Oliver SE. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 vaccine—United States, 2020. MMWR. 2020; 69.
Adhikari SP, Meng S, Wu Y-J, Mao Y-P, Ye R-X, Wang Q-Z, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis poverty. 2020;9:1–12.
doi: 10.1186/s40249-020-00646-x
Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395:1763–70.
doi: 10.1016/S0140-6736(20)31189-2
Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020;323:1612–4.
doi: 10.1001/jama.2020.4326
Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8:475–81.
doi: 10.1016/S2213-2600(20)30079-5
Liu W, Tao Z-W, Wang L, Yuan M-L, Liu K, Zhou L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J. 2020. https://doi.org/10.1097/CM9.0000000000000775 .
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–9.
doi: 10.1001/jama.2020.1585
Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–5.
doi: 10.1016/j.ijid.2020.03.017
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
doi: 10.1016/S0140-6736(20)30183-5
Miyashita H, Mikami T, Chopra N, Yamada T, Chernyavsky S, Rizk D, et al. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City. Ann Oncol. 2020;31:1088–89.
Guan W-J, Liang W-H, Zhao Y, Liang H-R, Chen Z-S, Li Y-M, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis. Eur Respir J. 2020;55:2000547.
He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, et al. COVID-19 in persons with haematological cancers. Leukemia. 2020;34:1637–45. https://doi.org/10.1038/s41375-020-0836-7 .
doi: 10.1038/s41375-020-0836-7
pubmed: 32332856
Gavillet M, Klappert JC, Spertini O, Blum S. Acute leukemia in the time of COVID-19. Leuk Res. 2020;92:106353.
doi: 10.1016/j.leukres.2020.106353
Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10:783–91.
pubmed: 32345594
pmcid: 7309152
doi: 10.1158/2159-8290.CD-20-0422
ElGohary GM, Hashmi S, Styczynski J, Kharfan-Dabaja MA, Alblooshi RM, de la Camara R, et al. The risk and prognosis of COVID-19 infection in cancer patients: a systematic review and meta-analysis. Hematol/Oncol Stem Cell Ther. 2020. https://doi.org/10.1016/j.hemonc.2020.07.005 .
World Health Organization. Clinical management of COVID-19: interim guidance, 2020. World Health Organization, 2020.
Niederwieser D, Baldomero H, Atsuta Y, Aljurf M, Seber A, Greinix HT, et al. One and half million hematopoietic stem cell transplants (HSCT). Dissemination, trends and potential to improve activity by telemedicine from the Worldwide Network for Blood and Marrow Transplantation (WBMT). In: American Society of Hematology Washington, DC, 2019.
Haroon AAM, Aljurf M, Ahmed SO, Shaheen M, Hanbli A, Chaudhari N, et al. COVID-19 post hematopoietic cell transplant, a report of 11 cases from a single center. Mediterranean J Hematol Infect Dis. 2020;12:e2020070–e2020070.
doi: 10.4084/mjhid.2020.070
Onaka T, Iwai F, Kato-Ogura A, Yonezawa A. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection after allogeneic stem cell transplantation. Clin Case Rep. 2020;8:1791–92.
Lu X, Tang LV, Wang H-F, You Y, Wang Y-D, Hu Y, et al. The great challenge of managing recipients of hematopoietic stem cell transplantation combined with COVID-19. Bone Marrow Transpl. 2020:1–5.
Huang J, Lin H, Wu Y, Fang Y, Kumar R, Chen G, et al. COVID-19 in posttransplant patients a report of 2 cases. Am J Transpl. 2020;20:1879–81.
Vicent MG, Martinez AP, Del Castillo MT, Molina B, Sisini L, Moron-Cazalilla G, et al. COVID-19 in pediatric hematopoietic stem cell transplantation: the experience of Spanish Group of Transplant (GETMON/GETH). Pediatr Blood Cancer 2020;67:e28514.
Pinana JL, Martino R, Garcia-Garcia I, Parody R, Morales MD, Benzo G, et al. Risk factors and outcome of COVID-19 in patients with hematological malignancies. Exp Hematol Oncol. 2020 25;9:21. https://doi.org/10.1186/s40164-020-00177-z . eCollection 2020. 2020.
Varma A, Kosuri S, Ustun C, Ibrahim U, Moreira J, Bishop MR et al. COVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter, Leukemia. 2020;34:2809–12. https://doi.org/10.1038/s41375-020-01019-x . Epub 2020 Aug 14, 2020.
Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7:e737–745.
doi: 10.1016/S2352-3026(20)30251-9
Shah GL, DeWolf S, Lee YJ, Tamari R, Dahi PB, Lavery JA, et al. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin Invest. 2020;130:6656–67.
Sharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist J, Chemaly RF, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021;8:e185–93.
Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907–18.
doi: 10.1016/S0140-6736(20)31187-9
Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323:2052–9.
doi: 10.1001/jama.2020.6775
Zamperlini-Netto G, Fernandes JF, Garcia JL, Ribeiro AAF, Camargo LFA, de Moraes Terra C, et al. COVID-19 after hematopoietic stem cell transplantation: report of two children. Bone Marrow Transpl. 2020;56:713–5.
Wood WA, Neuberg DS, Thompson JC, Tallman MS, Sekeres MA, Sehn LH, et al. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv. 2020;4:5966–75.
doi: 10.1182/bloodadvances.2020003170
Malekhosseini SA, Nikoupour H, Gholami S, Shamsaeefar A, Arasteh P, Kazemi K, et al. A report of 85 cases of COVID-19 and abdominal transplantation from a single center: what are the associated factors with death among organ transplantation patients. Transplantation. 2020;105:90–9.
Sharma P, Chen V, Fung CM, Troost JP, Patel VN, Combs M, et al. COVID-19 outcomes among solid organ transplant recipients: a case-control study. Transplantation. 2020;72:269A–70A.
Nair V, Jandovitz N, Jhaveri KD, Molmenti E. COVID-19 and solid organ transplant outcomes. Nephrol Dial Transpl. 2020;35:1444–6.
doi: 10.1093/ndt/gfaa207